Geode Capital Management LLC recently announced the acquisition of new stake in Moleculin Biotech Inc (NASDAQ:MBRX). The institutional investor has increased its shareholding in the Healthcare company by 0.09% to 0.25 million shares with purchase of 219.0 shares. This fresh investment now brings its stake to 0.83% valued currently at $0.15 million. In addition, BlackRock Fund Advisors raised its holdings by 102.0 to 0.2 million shares.
With over 0.49 million Moleculin Biotech Inc (MBRX) shares trading Friday and a closing price of $0.86 on the day, the dollar volume was approximately $0.42 million. The shares have shown a positive half year performance of 48.31% and its price on 12/29/23 gained nearly 14.45%. Currently, there are 29.81M common shares owned by the public and among those 28.84M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 14 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, accounting for 178,505 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 43,572 shares.
The top 3 mutual fund holders in Moleculin Biotech Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.62 million shares of the company’s stock, all valued at over $0.37 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.48% of the shares outstanding.
Shares of Moleculin Biotech Inc (NASDAQ: MBRX) opened at $0.77, up $0.02 from a prior closing price of $0.75. However, the script later moved the day high at 0.8600, up 14.45%. The company’s stock has a 5-day price change of 28.16% and 100.80% over the past three months. MBRX shares are trading -19.02% year to date (YTD), with the 12-month market performance down to -24.70% lower. It has a 12-month low price of $0.34 and touched a high of $1.65 over the same period. MBRX has an average intraday trading volume of 174.65K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 40.42%, 50.87%, and 37.45% respectively.
Institutional ownership of Moleculin Biotech Inc (NASDAQ: MBRX) shares accounts for 7.22% of the company’s 29.81M shares outstanding. Mutual fund holders own 3.26%, while other institutional holders and individual stakeholders account for 4.41% and 2.81% respectively.
It has a market capitalization of $25.59M and a beta (3y monthly) value of 1.98. The earnings-per-share (ttm) stands at -$0.90. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.42% over the week and 9.07% over the month.
Analysts forecast that Moleculin Biotech Inc (MBRX) will achieve an EPS of $Moleculin Biotech, Inc. for the current quarter, $0.86 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Veradigm Inc. while analysts give the company a high EPS estimate of $Mangoceuticals, Inc.. Comparatively, EPS for the current quarter was $Brixmor Property Group Inc. a year ago. Earnings per share for the fiscal year are expected to increase by 13.12%, and 7.98% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Moleculin Biotech Inc (MBRX) as a “Strong Buy” at a consensus score of 1.00. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the MBRX, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on July 18, 2022, with the firm’s price target at $14.
